The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000661370p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
7/05/2026
Date registered
Help: Date registered
3/06/2026
Date last updated
Help: Date last updated
3/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
3/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Feasibility of using non-invasive brain stimulation to improve outcomes in patients with Achilles Tendinopathy
Scientific title
Feasibility of using transcranial direct current stimulation to improve outcomes in patients with Achilles Tendinopathy: A protocol for a triple blinded randomised controlled pilot trial
Additional trial identifiers [1] 317216 0
NA
Universal Trial Number (UTN)
Trial acronym
tDCS-AT
Related trial records

Health condition
Health condition(s) studied:
Achilles tendinopathy 341818 0
Condition category
Condition code
Musculoskeletal 337886 337886 0 0
Other muscular and skeletal disorders
Physical Medicine / Rehabilitation 337887 337887 0 0
Physiotherapy

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants will undergo an 8-week exercise intervention consisting of 24 strength-training sessions (3 times per week) using transcranial direct current stimulation (tDCS). The exercise intervention used is informed by previous research and will be identical between the groups, to allow us to assess the feasibility, acceptability and effectiveness of the tDCS intervention independently to the exercise intervention.
To complete the exercise intervention, participants will be provided a 16-week gym membership (8-weeks during the intervention and 8-week follow up period) at the provider physiotherapy clinic, but they may alternatively perform the intervention at a location of their choosing. As per the intervention outlined by Van Der Vilst & colleagues (2020) (ClinicalTrials.gov NCT02996409), the program will consist of three consecutive phases: (1) isometric-focus, (2) concentric-focus, and (3) eccentric-focus. The isometric-focus phase consists of a single leg straight knee heel raise hold and a single leg bent knee (seated) heel raise hold, participants will hold for 45 seconds for a total of 3-4 repetitions. The concentric-focus phase consists of single or double leg heel raises completed with a straight knee and a bent knee (seated) with weight specific to the participant, they will complete 3 sets of 15 repetitions. The eccentric-focus phase consists of raising up on both toes, then slowly lowering for the count of 4 on the affected side. This will be completed with the knee straight and bent, for 3 sets of 15 repetitions. Participants will perform the exercises one-on-one with the physiotherapist at the start, and at each progression point in 30-minute supervised exercise sessions during week 2, 4 and 6. Participants can progress to the next phase or increase the weight when Achilles pain is less than or equal to 3/10 on the visual analogue scale (VAS) within the 24 hours following exercise. If a participant has a flare up in symptoms (Achilles pain greater than or equal to 5/10 VAS within the 24 hours following exercise), the exercises will be regressed in intensity, or they will return to the exercises in the previous phase. Exercise videos and descriptions will be delivered to participants via physitrack (https://www.physitrack.com/en-au). Physitrack will also monitor participant adherence to the exercise program.
The tDCS device (Brain Premier tDCS E1 Plus) will deliver a weak current (2 milliamps [mA]) from a 35 x 35 mm anodal electrode on the scalp at the vertex (overlaying primary motor cortex of the more symptomatic limb) to a cathodal electrode placed over the deltoid tubercle of the upper arm (on the contralateral arm to the symptomatic limb). The primary researcher (MEC) will train the participants how to self-perform tDCS on unsupervised days and will be available to help if required during these un-supervised sessions. Participants will set up and turn on the device before commencing their rehabilitation exercises. They will keep the device on for the 20-minute dose, after which they may remove the device and continue their exercises if necessary. Physitrack will monitor adherence.
Intervention code [1] 333982 0
Rehabilitation
Intervention code [2] 333983 0
Treatment: Devices
Description of the comparator or control
Both groups will undergo the 8-week exercise intervention. One group will use "real" tDCS and the other group will use "sham" tDCS. Real tDCS will be performed at 2 mA for 20 min whilst completing exercise rehabilitation. The sham tDCS will be applied during exercise with the placebo setting active which includes a ramp stimulation to provide the sensation of tDCS, then dropping to no output with the screen falsely reporting 2 mA of output.
Control group
Placebo

Outcomes
Primary outcome [1] 345331 0
Acceptability
Timepoint [1] 345331 0
8 weeks following commencement of the rehabilitation program
Primary outcome [2] 345332 0
Feasibility
Timepoint [2] 345332 0
baseline, 8 weeks following commencement of the rehabilitation program, 16 weeks following commencement of the rehabilitation program
Primary outcome [3] 345524 0
Safety
Timepoint [3] 345524 0
Safety will be assessed for the duration of the participants enrolment within the study
Secondary outcome [1] 461314 0
Protocol effectiveness
Timepoint [1] 461314 0
8 weeks following commencement of the rehabilitation program and 16 weeks following commencement of the rehabilitation program
Secondary outcome [2] 461315 0
Maximal plantar flexor strength
Timepoint [2] 461315 0
Baseline, 8 weeks following commencement of the rehabilitation program
Secondary outcome [3] 461316 0
Plantar flexor voluntary activation
Timepoint [3] 461316 0
Baseline, 8 weeks following commencement of the rehabilitation program
Secondary outcome [4] 461317 0
Plantar flexor strength-endurance
Timepoint [4] 461317 0
Baseline, 8 weeks following commencement of the rehabilitation program

Eligibility
Key inclusion criteria
We will recruit individuals aged over 18 years old with a clinical diagnosis of mid-portion Achilles tendinopathy, made via an experienced sports physician, over a 12-month period. Clinical diagnosis criteria will be primary location of pain at the midportion of the Achilles tendon mainly provoked under loading (e.g., running, hopping) with next day stiffness within the Achilles tendon.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants will be excluded if they have: no palpation tenderness on the Achilles tendon mid-portion region, insertional Achilles tendinopathy, no radiological evidence of Achilles tendinopathy on MRI, pain duration < 3 months, previous significant lower limb injury or surgery on the included limb which resulted in a time loss from activity (e.g., anterior cruciate ligament reconstruction, Achilles tendon rupture), history of invasive intervention (e.g., open, endoscopic or ultrasound guided) on the Achilles tendon, non-invasive treatment on the Achilles tendon (e.g., physiotherapy, iontophoresis) within the last 12 months, neurological conditions (e.g., stroke, multiple sclerosis), cardiometabolic conditions (e.g., diabetes), inability to commit to rehabilitation, inability to understand English and specific tDCS contraindications

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment was achieved using coded tDCS device modes (mode 1 and mode 2), with the intervention corresponding to each mode concealed from study staff.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Using randomisation table generated by Computer software (excel).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Statistical methods / analysis
All data will be described at baseline and across each time point using mean, standard deviation, median, interquartile range, minimum and maximum as appropriate. The results of primary outcome measures (acceptability and feasibility) will be provided descriptively in tables compared to the a priori criteria. Secondary outcome measures will be assessed by comparing change between groups with relevant covariates included. Data distributions will be examined for each outcome using Shapiro Wilk test and will guide between group test selections. Beta values and 95% confidence intervals will be provided, p-values will not be reported as this is a pilot feasibility trial. Complete case analysis will be conducted as recommended in the CONSORT guidelines. All statistical analyses will be performed in R language and environment for statistical computing (version 4.4.3).

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA

Funding & Sponsors
Funding source category [1] 321793 0
Commercial sector/Industry
Name [1] 321793 0
SportsMed Subiaco
Country [1] 321793 0
Australia
Funding source category [2] 321886 0
University
Name [2] 321886 0
The University of Notre Dame Australia
Country [2] 321886 0
Australia
Primary sponsor type
University
Name
The University of Notre Dame Australia
Address
Country
Australia
Secondary sponsor category [1] 324643 0
None
Name [1] 324643 0
Address [1] 324643 0
Country [1] 324643 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320338 0
The University of Notre Dame Australia Human Research Ethics Committee
Ethics committee address [1] 320338 0
Ethics committee country [1] 320338 0
Australia
Date submitted for ethics approval [1] 320338 0
12/05/2026
Approval date [1] 320338 0
Ethics approval number [1] 320338 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150138 0
Ms Molly E Coventry
Address 150138 0
SpotrsMed Subiaco. Suite 101/175 Cambridge St, Subiaco WA 6008
Country 150138 0
Australia
Phone 150138 0
+61 499633694
Fax 150138 0
Email 150138 0
Contact person for public queries
Name 150139 0
Molly E Coventry
Address 150139 0
SportsMed Subiaco. Suite 101/175 Cambridge St, Subiaco WA 6008
Country 150139 0
Australia
Phone 150139 0
+61 499633694
Fax 150139 0
Email 150139 0
Contact person for scientific queries
Name 150140 0
Molly E Coventry
Address 150140 0
SportsMed Subiaco. Suite 101/175 Cambridge St, Subiaco WA 6008
Country 150140 0
Australia
Phone 150140 0
+61 499633694
Fax 150140 0
Email 150140 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Data will be de-identified

What individual participant data might be shared?
• De-identified individual participant data:
• All outcomes data
• Published results
• Primary outcome(s)
• Safety data
What types of analyses could be done with individual participant data?
• Any type of analysis (i.e. no restrictions on data re-use)
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Studies testing whether findings can be repeated or confirmed
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
Not yet decided
Where can requests to access individual participant data be made, or data be obtained directly?
• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.